CA Patent

CA2578790A1 — Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen

Assigned to LYLE CORPORATE DEVELOPMENT Inc · Expires 2007-06-16 · 19y expired

What this patent protects

Methods and formulations for the regeneration of vaginal tissue and vaginal cell health resulting from vaginal cell hypoxia in a human female. A pharmaceutical composition for topical non-systemic administration is formulated containing a hormonal agent administered to the vagina…

USPTO Abstract

Methods and formulations for the regeneration of vaginal tissue and vaginal cell health resulting from vaginal cell hypoxia in a human female. A pharmaceutical composition for topical non-systemic administration is formulated containing a hormonal agent administered to the vagina, vulvar area of the individual undergoing treatment.

Drugs covered by this patent

Patent Metadata

Patent number
CA2578790A1
Jurisdiction
CA
Classification
Expires
2007-06-16
Drug substance claim
No
Drug product claim
No
Assignee
LYLE CORPORATE DEVELOPMENT Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.